Merit Financial Group, LLC Cytom X Therapeutics, Inc. Transaction History
Merit Financial Group, LLC
- $9.62 Billion
- Q3 2025
A detailed history of Merit Financial Group, LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Merit Financial Group, LLC holds 53,243 shares of CTMX stock, worth $211,907. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,243Holding current value
$211,907% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CTMX
# of Institutions
94Shares Held
123MCall Options Held
305KPut Options Held
121K-
Vr Adviser, LLC New York, NY14MShares$55.6 Million6.28% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$44 Million1.5% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.38MShares$37.3 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.46MShares$33.7 Million0.69% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.08MShares$32.2 Million0.04% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $262M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...